A phase IIIb, efficacy, and safety study of rosuvastatin in children 10-17 years of age with heterozygous familial hypercholesterolaemia: a 12-week, double-blind, randomized, multicenter, placebo-controlled study with a 40-week, open-label, follow-up

Trial Profile

A phase IIIb, efficacy, and safety study of rosuvastatin in children 10-17 years of age with heterozygous familial hypercholesterolaemia: a 12-week, double-blind, randomized, multicenter, placebo-controlled study with a 40-week, open-label, follow-up

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2011

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Acronyms PLUTO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Nov 2010 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Results published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top